Product Images Glipizide ER
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 4 images provide visual information about the product associated with Glipizide ER NDC 0591-0844 by Actavis Pharma, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
structure - image 1
NDC 0591-0900-30 - image 2
This is a medication label for a Glipizide extended-release tablet. Each tablet contains 2.5 mg of Glipizide USP. The dosage information can be found in the package insert. The tablets are manufactured for Teva Pharmaceuticals USA, Inc. There is also a serialization coding area on the label. Pack size options include 30 tablets.*
NDC 0591-0844-01 - image 3
This is a medication description for GlipiZIDE extended-release tablets manufactured by Teva. The tablets are available in a bottle of 100 tablets, and each tablet contains GlipiZIDE 5 mg. Dosage information can be found in the package insert. The medication should be stored in a tight container at controlled room temperature. However, it is not possible to determine the complete description from this text with incorrect spellings, missing words and random characters.*
NDC 0591-0845-01 - image 4
This is a description of Glipizide Extended-Release Tablets, manufactured by Teva. The package contains 100 tablets with dosage information available on the package. The tablets should be kept in a tightly sealed container and stored at room temperature (between 15-30 °C). The manufacturer, TOR Farmaceutiols UA Inc., is based in Daspiany. The code 591-0845-01 appears to be a product identification code.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.